Trial Information

Summary: Hypertension Study CSPA100A2305

The purpose of this clinical research trial is to find out if aliskiren (Tekturna®) alone and in combination with amlodipine (Norvasc®) is safe and will lower blood pressure in participants with high blood pressure.
Aliskiren (Tekturna®) is a medicine which has recently been approved by the US Food and Drug Administration (FDA) for the treatment of people with high blood pressure and is already available for sale in the U.S.
Amlodipine (Norvasc®) belongs to a class of drugs called "calcium channel blockers (CCB)". It is also approved by the US Food and Drug administration (FDA) and is available for sale in the U.S.
The combination of aliskiren and amlodipine is considered investigational. The word investigational means that the combination of aliskiren and amlodipine is still being tested and is not approved by the FDA and is NOT available for sale in the U.S.

Participants will be required to visit the study center approximately 7 to 11 times over a duration of 10 to 13 weeks. Each visit will take about 1-2 hours.
www.NovartisClinicalTrials.com

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: November 21, 2008 at 2:56:27 PM